Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It will get there and they have data coming out for BFPET in 1H'14. Exercising patience as the risk/reward isn't bad, IMO, and it represents a good early opportunity and additional diversification.
Oh is that all it needs? Lol
No interest here...dead money IMO
Great that it is holding steady regardless of outside factors and a red day in the market. Now that we have a strong base of Longs, FPMI just needs a bit of exposure & additional interest to pick the pps up again.
Good DD article from last year. http://www.dicardiology.com/article/pet-vs-spect-%E2%80%94-will-pet-dominate-over-next-decade
THANKS Biotrack!!! We are positions well here with FPMI. I'm liking how the risk/reward scenario sets up for us, which is why I'm sleeping well at night holding this full position. Like I often to to stay focused and to remind my self why I became interested in the first place; I reread the "State of the Union" PR from last July as well as the PET vs SPECT article linked within the SOTU PR. Really liking my decision to place my money here and feel that as this microcap Biotech continues to grow, and when the lights are really shining on this "Diamond in the OTC Rough", those of us that had confidence and capital sill be very happy and amply rewarded!!!
Happy March 1st!!!!
RR
I love your transcript from the call. Seems like a great place to park money for the eventual win. If exposure is the key, it happens and it happens big w/ OTC at the right time fir companies with the proper product&vision. Very excited Rhodey!
UPDATE: Just got off the phone with CEO Thijs Spoor. Outstanding 22 minute conversation. Easily could have been 45 minutes, but he had more than answered all of the questions I had written down beforehand and the last thing I wanted to do was be rude, keep him on the line unnecessarily and do damage to this friendly informational relationship that we are developing here.
I am still digesting alot of the information and some of it I am going to research a bit more so that i have it 100% right and that I am diseminating it accurately and appropriately.
A couple personal thoughts for tonight:
1) That is one intelligent guy. He knows his numbers and has the company direction fully in focus!! Just listening to his theory and explanation of Risk Adjusted Valuations for Flouropharma is worth the price of admission!!! (My confidence is enthusiastically high)
2) Regardless of the potential for significant momentum moves, this is without a doubt a longer term investment! (I will be trimming on large spikes and adding on significant dips)
A couple clear points from our discussion:
1) After our recent financing via Private Placements we have enough capital through August '14. At that time, another round of financing will be necessary. As always, non-dilutive forms of financing that have beneficial terms for the company are being sought, (but as I have posted in the past I am not bothered by Private Placements to knowledgable investors and insiders (especially repeat investors) as a form of raising necessary capital to continue operations. Dilution Happens People!!
2) The Confidential Treatment Order (CTO) that was recently granted us by the SEC is a positive event for us. It is protecting the favorable licensing terms that we have with Massachusetts General Hospital. (Thats it plain and simple.)
3) Data results from our Phase II BFPET trial are on schedule to be released in the 1st Half of '14 as previously stated. The exact nature of the data to be released and the specific date of the release are confidential as of right now.
***** As you recall, the Positive Data release for our Phase II in CARDIOPET was also slated for 1st half of '14 and that came out on February 6th, 2014. That Data release came out in conjunction with a scheduled conference appearance. Mr. Spoor stated that he likes to release data in conjunction with conference appearances. That being said, we can assume that when there is a PR for an upcoming conference within the 1st half of '14, that the chances are above average that we will also be getting a catalyst of a data release for our Phase II in BFPET around the same time.
******* An interesting point to know, Thijs wasn't available this afternoon to chat on the phone because he was in meetings with his Investor Relations Department to discuss the topic of which upcoming Bio-Conferences to put on the schedule.
As I stated earlier, I have to digest a few other bits of information and do a little more homework on several items of information but will get those out to the board ASAP.
Hopefully, this very quick disemination of cursory information will be useful to many of you in making your investing decisions regarding FPMI.
Have A great evening everyone!!!
RR
Looking back at the charts from the previous 2 yrs we have a couple of spikes each year in the 20-30% range...we'll just need to be patient here 1-3months, IMO
I liked what I saw here today. Just a matter of time on this one.
Last 5 minutes of trading saw 40K in buys come through with 30K at .57 where we ended the day. 40 K is 1/3 of our normal daily average people. Very Very Bullish IMO!!!
Solid move on volume today. Hopefully this puts you in a little better mood IF69. Seems this was a typical "oversold territory" move up on no news. IMO we have been very oversold and it would be nice if .50 was our solid support and we can start a healthy uptrend in the latter part of this quarter.
On another note, I shot out a message to Thijs Spoor early this morning with several questions and we played phone tag throughout the day. Just the fact that the CEO is willing to take the time to reach out to an individual investor such as myself should make this board feel a little better as to the level of courtesy and professionalism that management has displayed. Hopefully we can hook up tomorrow because Im really hoping to get a crystal clear picture of our near term catalysts and company direction for 2014. When I hear back I will certainly pass along any pertinant information to this board regarding company direction and pending catalysts.
Again up over 11% on almost 3X volume is a very good day. Enjoy the green arrows people!!!
I see we are a little jiggy today. Somewhat better than average volume and up about 8%.
What a POS this turned out to be....just supports my theory that the only reason this had some nice days was via SheffStation.
Good Morning Steve (on ihub board #2). I'm working hard on getting some specifics for us. Will absolutely get them to you when I have anything of signiftcance.
Rhodey...so were there given any specific dates for catalysts coming in the future?
Steve
Interesting morning action toward the positive today. would like to see volume continue throughout the day. That early 5K trade at .60 was peculiar. nice to see, but peculiar all the same. Looks like a decent morning for Bio-tech overall which always helps. ive continued to accumulate on dips and hopefully those of you that are loking for longerterm gains vs. shorter term trades are as well. with the small number of outstanding shares this stock will move quickly on news, which is why I have heavily positioned myself at these levels. heading off to work and will check back in this evening. Best to everyone~ RR
If69, you wouldn't be the first to post that sentiment. Being a positive guy I try to see the best in things and people. Though I get your point. I am envious of his stated returns, who wouldn't be. And you could be right about his timing of trades/posts. Hard to know for sure. But I am not hardwired to hate so I will give him his props. I like his DD heads up, and I do my own from there. I don't leap on his moves by any means. He sold his MSTX recently for a small gain. I held mine, added on dips from his sell alert and watched my larger position gain over 100%. Trimmed a bit of profit and holding rest much longer and have added on recent pullback. (Disclaimer...I also moderate MSTX board) point being... I take the positives that he presents but don't buy in to the sheepish religion like some. Can't see you objecting to that IF69!!!
Now on to FPMI, are you on board and excited for this company, just visiting and checking things out or other????
He is NO guru....sorry but I disagree. He is a lucky individual who hit it big on a few trades many years ago and created a following. That following has grown and made him millions. All his gains are timing related and require NO biotech knowledge. A catalyst is timing driven and he plays that with his thousands of followers and is pretty much guaranteed 10% profit on every single trade he makes.
FPMI if such a great stock like he stated....then why sell? He's nothing but a Pump and Dump champion! I GUARANTEE he owns his picks much earlier than he states and when all his "sheep" jump in....he sells. It's laughable how everyone puts that putz on a pedestal!
Investor Freak, You are referring to the "Sheff Effect" via Sheffs Station board. Absolutely, his stock alerts and his followers actions seriously influence stock movement on both buys and sells. His DD is outstanding and his was the alert that started my DD on the company. Love his page and the serious stock discussions that are on it.
On 1/10/14 FPMI opened with a gap up of .08 cents at .60 from a previous close of .52 The Forbes article states a time on it of 10:20ish or something like that, though I believe that the article was out before that in some form or fashion for investors to act on the positive information, however that it pure speculation on my part.
Also, Sheffs Stock alert that he had entered FPMI didn't come until the 3:51 hour. In the alert post (pasted below) he brings attention to the Forbes Article I was referencing:
$heff
Friday, 01/10/14 03:51:11 PM
Re: None
Post # of 77540
Beginner Portfolio Update..bought a stock today that has a solid pending catalyst and its technology was written up in Forbes magazine today. After more research learned of some key catalysts ahead. 52wk range is $.48-$.91. 60K in volume traded today.
Key stats on the company are here. It’s right near its 52wk low. 15m market cap. 16.5m in float and 24m O/S. 3.3m in cash and 55k debt. http://finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
Alert..bought starter FPMI at $.60 in the beginner portfolio for a trade. Fully reporting OTCBB biotech/medical play with solid catalysts with dates approaching.
Form 4 filing by the CEO on Jan 7th. http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=9700721
8-k just filed as well. http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=9698986 to sell shares to Platinum at $.50
PET Imaging Market Poised To Grow With New Compounds - Forbes on Jan 10th, 2014.. http://onforb.es/1cV0qdM
FluoroPharma CEO Thijs Spoor to Provide Business and Portfolio Update at Biotech Showcase 2014 in San Francisco, January 13th-15th - http://yhoo.it/1anNGA0
FluoroPharma Medical Announces Acceptance of Abstract for Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Winter Meeting Feb - http://yhoo.it/1fjW1J7
Now ususally Sheff alerts right after a purchase, but sometimes he is very busy and they dont come out till later in the day. Clearly that must be the case here because the stock must have been closer to .70+ when the alert came out for it to close at .76. perhaps it pulled back for his late entry, i dont have the days chart in front of me, but you get my point.
Lets agree that both Sheff and the Forbes article played a roll in the stock moving a huge percentage on 1/10/14.
Now, Sheff did sell on the day of our P2 data release at .65 for an 8% gain and the stock did retreat immediately following his alert of his sale. You are correct. and the stock has continued to decline from there to our present price of .52.
Now Sheff had been warning since late Decemeber that he was going to pull the trigger on profits much quicker than normal because of the sketchy nature of the market at the time. I have no problem with that strategy. he is BIOtech investing guru IMO. However, I have more of a long term approach overall, and especially with this company. I like the long term story and will be holding long, buying on dips and hopefully reaping the rewards of my hard earned dollars as this company brings my expectations to fruition. This is not a stock for everyone. it is not a day traders dream. But the NextGen Technology is IMO OUTSTANDING!!! Risk and Reward at its finest!!!! Have a wonderful weekend everyone!!! and if you are in the Northeast like me...buckle down tonight because the blizzard is fierce here on the South Shore!!
Get real! The only reason this penny stock moved recently was because another Ihub member with a huge following bought in...it spiked. He recently sold and everyone bailed.....we are back to exactly where it was before he bought!
Its that simple!
Some answers I was asked to post on regarding recent SEC filings:
Several posters reached out privately for my opinion on recent SEC filings by Flouropharma. I have digested the recent filings, previous years filings and also research industry related documents in the area of interest to form an accurate personal opinion for you. I will provide a general opinion that is to the point and not jammed with data that usually makes peoples eyes spin and glaze over.
The main question was about shares, effects of dilution and company financials:
Clinical research and development Biotech companies in the early stages all burn cash and have little to no revenue. Everyone knows this. Companies need to raise capital to fund business. Capital is raised through equity offerings or debt. If capital via debt cannot be raised with good borrowing terms than equity offerings is the standard alternative. Offering equity does have a dilutive effect for existing stock holders. Everyone knows this. It is an inescapable fact for the biotech industry as they work through the long (and exciting) development process. However, the type of equity offering has different effects on stock price historically.
Large public offerings vs. Private Placements.
Instead of large public offerings of stock, FPMI has historically raised capital with Private Placements. Private placement info is everywhere online of you want to read up more on your own. PP are institutions, knowledgeable industry savy investors and insiders for the most part. FPMI has raised capital several times via PP and the latest was in February '14. Using PP, though dilutive, is often looked at as a positive evil, because the investors are insiders, or extremely knowledgeable about the potential and future of the company. ALSO, when the same investors take part in numerous consecutive PP offerings, it again shows confidence in the long term potential of the company and their pipeline. Also, PP offerings usually signal that these investors feel the stock is undervalued. THIS IS WHAT WE HAVE HERE WITH FPMI AND WHY I AM EXTREMELY CONFIDENT ABOUT THIS STOCKS POTENTIAL! Yes, there has been dilution and yes there will be future dilution. It is a fact of early biotech life. Everyone knows this. We currently have sufficient cash (no debt) according to the company until August of 2014. If partnerships or other funding isn't acquired by then, then they will have to logically repeat this process. I am 100%fine with this scenario. As long as the data is positive I am holding long with this company. I will buy on any significant dips and smile on any significant spikes from positive news and trial catalysts. That has proven to be a successful investment strategy for me historically when the future potential of the company is as big as Flouropharmas is. So again the highlights of this post are as follows:
Raising capital is necessary
Using Private Placements is a good option compared to alternatives
Having insiders and repeat investors is very positive
This stock is undervalued.
The future of this company is very strong
This post was a very abridged version of the information that I digested/gained in my research recently. If you have a specific question I will do my best to get you a specific answer. That would be the easiest, especially if it is a specific financial/share related question. This was not meant to be a 50 page analyst report. There is many are many printable undisclosed. Hence, my willingness to address specific questions. again, I am long with FPMI and will continue to add to my position unless the company news changes. Presently I am strong on FPMI for shareholder value.
Heading of to work now while the temps in Rhode Island are decent. Have a great weekend everyone and chat again soon. RR
Hey Hmoney, I see no reason why we wont revisit the highs of January that were in the .75-.76 range if memory serves me correctly. Thats a nice 50% upside from current levels, give or take a few percent. Clearly company news, analysts coverage and outside factors can move this stock quickly.
Do you have a price target for next 6 months?
Thanks Senderos. Firstly, I received your PM and will get something out on that by the end of the week.
Yes, this is easily one of my most exciting companies I own from a longer term perspective. This is a "changing of the guards" company in the imaging field and I'm stoked about the current data and the future potential for Flouropharma in this billion dollar industry. As CEO Spoor stated, we don't need to be the only game in town. The industry is big enough for a Coke and Pepsi. I don't mind being either.
This is certainly a longer term play then a flip trade. Not saying we won't get some spikes here and there, but the multibagger gains are further down the road. As the old imaging tech is phased out more and more, we will continue to grab market share.
Looking forward to many productive discussions regarding FPMI on this board. Have a great day everyone.
Rhodey: great DD last night. The FPMI media presentation helped me to decide to hold this stock longer than I had planned. The more I learn about PET technology, the more I like it as an investment.
Good evening everyone. I'm excited to be here on the FPMI board. I have a boatload of shares and will be holding with a longterm perspective unless the company news changes and at that point I like most investors will rethink my investment strategy for the position.
I had an excellent (and unexpected) conversation this afternoon with CEO Thijs Spoor. I had fired off a few emails recently with some questions about FPMI and I was pleasantly suprised and throughly impressed that he decided to reach out to me via a phone call.
I basically asked several questions to get a feel for managements strategy moving forward in 2014. Of course he could not and should not provide specifics, but the conversation was extremely positive and I walked away feeling excited for the potential of this company..and of course we the shareholders.
A few things I can share: We were indeed suppossed to give a presentation on Sunday the 9th at the mid-winter meeting. There was a schedule change and the data was presented on Thursday.
Mr. Spoor, without any specifics mentioned, assured me that 2014 would be a year chock full (my words)of news that should appropriately move our stock price. Please feel free to take that as you will, either positively or negatively. I of course take that as a positive.
Probabaly a few other things to share but it is getting late on the east coast and I have an early day tomorrow.
Have a great evening everyone.
Rhodey
Zacks Anaylist Reiterates $2.15 Price Target 2/7/14 http://finance.yahoo.com/news/fpmi-promising-phase-ii-data-160000729.html
Forbes Article That moved FPMI from .52 to .76 on 1/10/14 http://www.forbes.com/sites/johnfarrell/2014/01/10/pet-imaging-market-poised-to-grow-with-new-compounds/
FlouoroPharma Slideshow from 12/13 http://content.stockpr.com/fluoropharma/media/d1569342f8a53f7ba4117c6bb4cbb83d.pdf
Excellent Webcast: FPMI CEO Thisj Spoor http://noble.mediasite.com/mediasite/Play/df13c1504acd42dfb206711d92c32f511d
Did u not read my post I wrote awhile back.
Is today's sell off still the "$heff Effect"? What gives here...
already back up to 62!
yep thought the same thing. Unbelievable the amount of power he has LOL. I'm riding it out til next week, letting the dust settle. It's way undervalued now, hope there will be a few more PR's to get it moving again.
i hardly ever buy or sell same time especially otc that have less liquidity. wait for things to settle down and next thing we know POOF it's back up
Ouch, that hurts!!!
FPMI - Data Presented From FluoroPharma's Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Acute and Chronic Forms of Coronary Artery Disease (CAD)
Data Presented at 2014 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Winter Meeting Could Be an Important Development for Patients With Coronary Disease and Potential Compelling New Direction for PET Cardiac Imaging
Great volume today. Not causing the price to move but hopefully will continue at these levels going into the data read out this weekend.
It's a 4 day conference, Thursday - Sunday and their presentation slot is for Sunday at 9 am. Not sure when they'd formally release a PR with the data, I'm guessing Monday morning, or maybe Sunday. Either way yeah glad to see they are not working 9-5 M-F LOL.
They are posting something on a Sunday? Lol interesting... No weekends for them I guess
Getting really close to our catalyst here. $heff posted that they present on Sunday morning the 9th. Hope we start seeing some volume and early next week the market takes notice. I think we all expect the data to be stellar.
Seems you're just here to pump your own board. Can you Chill out with the spam
re. http://finance.yahoo.com/news/fluoropharma-medical-announces-acceptance-abstract-123000957.html
MONTCLAIR, NJ--(Marketwired - December 19, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that their Abstract has been accepted for oral presentation at the SNMMI winter meeting which will be held in conjunction with the Annual Meeting of the American College of Nuclear Medicine. Data from FluoroPharma's ongoing Phase II clinical trial for CardioPET (18F FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients, will be presented at the meeting scheduled for February 6-9 in Palm Springs, CA.
I didnt know if the specific day was announced. I didnt see on the conference website anywhere that they were presenting either.
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
371
|
Created
|
09/20/10
|
Type
|
Free
|
Moderators |
FluoroPharma Medical, Inc. 8 Hillside Ave Suite 207 Montclair, NJ 07042 Phone: (973) 744-1565 www.FluroPharma.com Info@FluoroPharma.com | MissionIR 3645 Marketplace Blvd. Suite 130-280 Atlanta, GA 30344 Phone: (404) 941-8975 www.MissionIR.com Editor@MissionIR.com |
FluoroPharma Medical, Inc. (FPMI) is focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The market growth for this imaging technology presents tremendous opportunity for innovative developments that address unmet medical needs. FluoroPharma is currently advancing four different imaging agents to fulfill these critical needs while providing clinicians important tools for detecting and assessing pathology before critical manifestations of disease.
Unlike traditional imaging modalities (MRI, CT, and Ultrasound) that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease non-invasively before anatomical manifestation is identified by offering visualization of biological processes at the molecular and cellular level.
Featuring higher resolution scans with only a third of the radiation dose, as well as higher levels of reimbursement, PET has become the preferred imaging technology for a variety of diseases and disorders.
For more information, visit www.FluoroPharma.com
Presentation FPMI.MissionIR.com/Presentation
CardioPET (coronary artery disease) is on track to start Phase IIb clinical trials by year end. This muscle state imaging agent exploits the dietary needs of the heart as it relates to glucose and fatty acids. By introducing a radio-labeled analog to the natural fatty acids utilized as an energy source by the heart, the technology allows for the visualization of the anatomic location and state of the muscle to detect problems in advance of symptoms that would lead to a stress test.
FluoroPharma believes that within the third year of launch, CardioPET could be used in approximately 700k procedures, growing to 1+ million procedures in the following five years. This could equate to a potential revenue opportunity to FluoroPharma of approximately $400 million in the third year (2019/2020) and $600+ million in the fifth year (2021/2022) after launch.
BFPET (coronary artery disease) Phase II clinical trial results are expected by year end. BFPET, a Flourine-18 labeled tracer, has been designed to enter the myocardial cells in direct proportion to blood flow and cell membrane potential. These are two of the most important physiological indicators upon which adequate blood supply to the heart depends. BFPET has been designed to differentiate among those cells of the myocardium that may be ischemic, infarcted and those that are healthy.
FluoroPharma estimates that BFPET could capture about 1% - 3% of the total market for MPI radiopharmaceuticals in the first full year after launch (possibly 2016/2017) and will account for about 20% - 30% of the market five years following launch (possibly 2021/2022). Contingent on the selling price that the Company is able to achieve, this could mean revenue from sales of BFPET as high as $50 million in the first full year after launch and $700 million five years after launch.
*CardioPET could be used in combination with FluoroPharma’s BFPET or other blood flow agents in performing Cardiac Viability Assessment (CVA)
VasoPET (coronary artery disease) is on track for Phase Ib clinical trial by year end. By targeting the active adenosine phosphate molecule receptors which are associated with inflammatory conditions this imaging agent allows us to visualize potential areas that may cause embolisms and thrombosis. VasoPET is designed for patients that have already had a heart attack or stroke with the risk of a potentially fatal recurrence.
FluoroPharma believes that VasoPET could be used in approximately 30k PET scans in the first full year of launch, growing to 450k and 700k scans in the third and fifth year (post-launch), respectively. Assuming a $600 cost per dose, this could result in revenue opportunity of $18 million in year one (2017/2018), $270 million in year three, and $420 million in year five (2022/2023).
AZPET (Alzheimer’s disease) is an imaging agent that attaches to the amyloid deposits (plaque) in the brain and makes them visible on a PET Scan, thus allowing the early detection of Alzheimer’s disease.
According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future - the global market for molecular imaging agents is projected to exceed $15 billion by 2015. With one in three patients dying because of heart disease, FluoroPharma's cardiovascular program addresses the largest segment of the nuclear medicine market.
The World Health Organization estimates that 7.3 million deaths were directly attributable CAD during 2008 (12.8% of all global deaths), making CAD the leading cause of death worldwide. In the United States alone, cardiovascular disease is responsible for 32%, or 1 in every 3 deaths, of all deaths.
FluoroPharma's comprehensive technology platform aims to help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment and better patient outcomes.
To date, the company has been issued patents related to its portfolio of imaging compounds in the United States, Europe, China, Japan, Canada, Australia, Finland, Portugal, Ireland, and Mexico. FluoroPharma is backed by a highly experienced management team and the necessary resources to advance clinical development and capitalize on its superior imaging technology.
Novel Cardiac PET Tracing Agents Market Forecast to grow by at least 14% Annually to Approximately $900 million by 2017
FluoroPharma’s products utilize positron emission tomography (PET) technology, a molecular imaging platform that is growing rapidly due to its inherently superior sensitivity and specificity compared to other imaging options. The company’s PET imaging products improve patient management by evaluating cardiac disease at the cellular and molecular levels.
Molecular Imaging Market
Molecular imaging fulfills unmet needs in diagnosis and follow-up therapy by enabling visualization, characterization, and measurement of biological processes at the molecular and cellular level. Unlike more commonly known imaging modalities – MRI, CT, and Ultrasound– that provide insight into the anatomical manifestation of disease, molecular imaging techniques provide insight into physiology and can detect disease before anatomical manifestation is identified.
Cardiovascular Market
Symptomatic coronary artery disease (CAD) affects more than 13 million patients and accounts for more than 30% of all deaths. Cardiologists’ demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic CAD. Molecular imaging is currently used in more than 9 million myocardial perfusion imaging (MPI) procedures, the standard test for diagnosing CAD.
Additional Diagnostic Markets
Approximately 5.2 million people in the United States are living with Alzheimer’s and 10 million Baby Boomers will develop the disease in their lifetime. Currently, there is no single diagnostic test that proves a person has AD. FluoroPharma is developing new options for early detection and treatment of Alzheimer’s, to improve patient care and create new paths for Alzheimer’s disease management.
Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States. FluoroPharma is developing new compounds to enable earlier and more accurate diagnosis of prostate cancer.
Following is a list of FluoroPharma’s patents and pending patents:
Cardiovascular and thrombus imaging agents, methods and kits
United States Patent 6,299,857
Elmaleh, et al.
Issued - October 9, 2001
Expires – December 27, 2016
Foreign patents granted: EP, JP, MX, FR, DE, CH, UK
Tumor imaging agents, methods and kits
United States Patent, 6,187,286
Elmaleh, et al.
Issued - February 13, 2001
Expires - December 27, 2016
Foreign patents granted: CA, MX, EP, AU
Imaging Agents for Early Detection and Monitoring of Cardiovascular Plaque
US Patent Pending No. 98 94 5939
Elmaleh, et al.
Utility (CIP): 09/530,818 #7060251
Granted - June 13, 2006
Expires - September 8, 2018
Utility: 11/286,930 #7,438,891
Issued - October 7, 2008
Expires - September 8, 2018
Foreign patents granted: AU DIV
Method for Monitoring Blood Flow and Metabolic Method for Uptake in Tissue with Radiolabeled Alkanoic Acid
Elmaleh et.al.
United States Patent No. 7,790,142 B2
Issued – September 7, 2010
Expires – February 3, 2025.
Foreign patents granted: EP, HK.
Catalytic Radiofluoronation
Elmaleh et. al.
United States Patent No. 7632485
Issued – December 15, 2009
Expires- February 24, 2025
Foreign patents granted: MX
Biotin Compounds for Targeting Tumors and Sites of Infection
Elmaleh et. al.
United States Patent No. 5716594
Issued – February 10, 1998
Expires – June 6, 2014
Foreign patents granted: JP, HK, EP, FR, DE, IE, UK
FluoroPharma has compiled a number of valuable online resources that pertains to the Company’s research. To read the latest industry news, learn about latest advances in molecular imaging diagnostics and therapy and understand emerging imaging technologies please click on any of the links below.
Radiology Links:
Cardiac Imaging Links:
Imaging Molecular Imaging Links:
Thijs Spoor Chairman of the Board, CEO & President
Thijs Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting. He has been a guest lecturer at Columbia Business School, Kings College in London, and the University of Newcastle in Australia, and has presented at medical grand rounds and psychiatric grand rounds at various hospitals on the role of brain imaging.
Spoor previously held the title of CFO for Sunstone BioSciences. Prior to joining Sunstone BioSciences, he worked as a consultant at Oliver Wyman where he helped pharmaceutical and medical device companies evaluate their global revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform.
Spoor has also been an equity research analyst at J.P. Morgan and Credit Suisse where he covered the Biotechnology and Medical Device industries. Spoor worked in the pharmaceutical industry spending 10 years with Amersham / GE Healthcare where he worked in seven countries in a variety of roles including setting up GMP facilities meeting ISO 9001 standards, accountability for the entire nuclear cardiology portfolio, and most recently as the Director of New Product Opportunities leading the PET strategic plan.
Boyan Goumnerov, MD COO & Vice President Clinical Trials
Dr. Boyan Goumnerov has held executive positions in the healthcare and biomedical research fields, the most recent being his role as president of VasoStent Inc. and managing director of CardioVas Inc., start-up medical device companies targeting the field of intravascular cardiac imaging and therapy. His academic background includes research within the departments of Surgery and Molecular Biology at the Massachusetts General Hospital (MGH) and The Shriners Burn Hospital for Children, Boston, where he held academic appointments with Harvard Medical School. Dr. Goumnerov also did extensive work within the Department of Pathology/Neuropathology at Children's Hospital Boston, in developing image analysis protocols for evaluation of neuromuscular diseases before moving to MGH. He is co-author of numerous scientific publications. Dr. Goumnerov obtained his M.D. from the Medical University of Sofia, Bulgaria, and worked as a clinician prior to relocating to the United States.
Tamara Rhein CFO
Before joining FluoroPharma in 2011 as Controller, Tamara Rhein was the Controller of Manhattan Pharmaceuticals where she was responsible for maintaining the critical financial functions as well as performing a wide range of activities including financial statement preparation, footnote disclosures for SEC filings, stock option accounting, and quarterly and year-end audits. Prior to Manhattan, Rhein was employed with Vyteris, where her primary role was to manage the SEC accounting and reporting department. In addition to her financial responsibilities, Rhein worked with the CEO on the launch of a new product. In this capacity, she managed critical aspects of coordination, timing, and tracking of the initiative.
Rhein also previously served vice president of New Business at Credit Suisse First Boston, where she provided comprehensive research and analysis to guide senior management on certain projects and complex business transactions; and vice president of External Reporting at Donaldson, Lufkin & Jenrette, where she prepared and reviewed SEC filings for Donaldson, Lufkin & Jenrette as well as Donaldson, Lufkin & Jenrette direct. She was extensively involved in the Initial Public Offering of the Donaldson, Lufkin & Jenrette direct tracking stock issued in May 1999.
Rhein began her career as a senior auditor for Deloitte & Touche, where she planned and administered audit engagements for several large banks and insurance companies. She received a Bachelor of Science in Accounting from California State University, and is a Certified Public Accountant.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |